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ECP is largely used in Acute and Chronic GVHD patients.
Moreover, some multicenter studies are ongoing to evaluate future
ECP employment in GVHD prevention. Therefore, laboratory
and clinical parameters predictive of ECP response would be ex-
tremely useful. For istance, recent published data shown great
interest on VBTCR oligoclonal CD4 or CD8 subsets, and T reg
CD4CD25 CTLA 4/-, which could be used as predictive
factors for GVHD outcome.
We present data from seriate, cytoﬂuorimetry phenotype studies
performed on 200 blood samples from 4 aGVHD and 13 cGVHD
patients that underwent ECP in our Apheresis Unit.
15/17 had skin involvement oral mucose and/or ocular disease,
3/17 showed liver GVHD, 2/17 had lung function compromised.
Schedule for ECP therapy established 6 and 12 months of treat-
ment for Acute or Chronic GVHD, respectively.Clinical evalua-
tion was made every three months and according to known pro-
tocols.Skin and oral mucosa improvement was achieved in the 64%
of the patients, liver recovery was stabilized in the 30%, while no
response was reported in lung function.
Finally, after more than 6 months of treatment, 3/14 cGVHD
patients failed to respond and 3/14 maintained stable disease with-
out steroids administration.
A pathological increment of the VBTCR CD4 or CD8 oli-
goclones (being ﬁxed as 15% of the circulating lymphocytes) was
found in 10/17 patients. VB20, VB16, VB14 and VB3 were the
most recurrent oligoclones, but we could ﬁnd only weak correla-
tions with ECP response-rate, kind and extension of GVHD. At
the start of ECP, Treg CD4CD25CTLA4 (mean 0.4% of
the circulating CD4) were detected in all 2 cGVHD and in 1
aGVHD early responders to ECP. This subset was lacking in 3
ECP refractory patients in which, on the contrary, was detectable
the subset CD4CD25CTLA4- (mean 1.6% of the circulating
CD4) also detectable in the other 11 remaining patients. Inter-
estingly, in this last group of subjects Treg cells seemed to be
correlated to the ECP response rate. In particular, responders
showed inverse trends in the CTLA4 (increasing) or CTLA4-
(decreasing) subsets during ECP treatment.
In conclusion, Treg subpopulations seem to be useful as predic-
tive factors of GVHD outcome, in accordance with other studies
results. Nevertheless, further research is still necessary in order to
draw deﬁnitive conclusions.
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CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE
1 IS AN IMPORTANT SUPPRESSOR OF INTESTINAL AND SYSTEMIC
ACUTE GRAFT-VERSUS-HOST-DISEASE
van den Brink, M.R.M.1, Willis, L.1, Bautista, J.1, Chow, M.1,
Smith, O.M.1, Cabrera-Perez, J.1, Suh, D.1, King, C.1,
Zakrzewski, J.1, Kochman, A.1, Hubbard, V.1, Turbide, C.2,
Beauchemin, N.2, Lu, S.X.1 1Memorial Sloan-Kettering Cancer Center,
New York, NY; 2McGill University, Montreal, QC, Canada.
Carcinoembryonic antigen related cell adhesion molecule 1
(CEACAM-1) is a transmembrane glycoprotein found on leukco-
cytes, endothelium, and epithelium, and its activation can attenu-
tate colitis in murine models. Microarray analysis revealed that
CEACAM-1 expression is increased during gut graft-versus-host-
disease (GVHD). We studied the role of CEACAM-1 in a mouse
allogeneic bone marrow transplantation model (B63BALB/c]).
Using CEACAM-1-/- mice as recipients or T cell donors caused
sigiﬁcantly worse GVHD (p0.05) compared to wildtype (WT)
controls.
Histopathological analysis of GVHD target organs from
CEACAM-1-/- recipients of WT T cells revealed signiﬁcantly
increased GVHD of the large bowel (p0.05) and the thymus
(p0.05) as compared with WT controls.
Additionally, alloreactive splenic CD8 CEACAM-1-/- T cells
from recipients with GVHD had increased levels of 
47 integrin
(LPAM) as compared to WT controls. We also found increased
numbers of intraepithelial lymphocytes and mesenteric lymph
node cellularity in CEACAM-1-/- recipients of WT T cells.
Furthermore, adoptive transfer of CFSE-labeled CEACAM-1-/-
T cells into WT hosts, or of WT T cells into CEACAM-1-/- hosts
revealed more profound activation of T cells in the CEACAM-1
deﬁcient setting as demonstrated by increased early CD25 expres-
sion and CD62L downregulation on fast-cycling alloreactive T
cells in the spleen and liver.
We found no signiﬁcant differences in serum levels of TNF-
 or
interferon-, T cell proliferation kinetics upon adoptive transfer,
percentages of alloactivated CD4 and CD8 cells, or percentages of
CD4FoxP3 regulatory T cells in WT recipients of CEACAM-
1-/- T cells, CEACAM-1-/- recipients of WT T cells, and WT
recipients of WT T cells.
We conclude that CEACAM-1 deﬁciency on donor T cells or in
recipients results in increased gut and systemic GVHD due to
increased T cell activation and expression of the gut homing
integrin 
47. This suggests that the use of CEACAM-1 agonists
could be a novel theraputic strategy for ameliorating acute intes-
tinal and systemic graft-versus-host-disease. Studies with an ago-
nistic CEACAM-1 antibody are currently under way.
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GLOBAL ASSESSMENT OF B CELL ALLOIMMUNITY USING MICROAR-
RAYS OF 5000 HUMAN PROTEINS
Wadia, P.P.1, Coram, M.1, Weintraub, L.1, Butte, A.1, Miklos, D.1
1Stanford University School of Medicine, Stanford, CA.
Allogeneic Hematopoietic Cell Transplantation (HCT) can cure
hematologic malignancies through beneﬁcial graft-v-leukemia (GVL)
allo-immune responses, but is limited by graft-versus-host disease
(GVHD). Recent studies demonstrate allogeneic antibodies (Ab) de-
velop against minor histocompatibility antigens (mHA) encoded on
the Y-chromosome (H-Y antigens) develop after sex-mismatch HCT
in association with chronic GVHD and persistent disease remission.
We hypothesize that novel mHA can be serologically identiﬁed as
targets of allo-Ab responses that develop post-transplant but are ab-
sent pre-transplant. ProtoArray™ (Invitrogen) displays 5,000 full-
length human proteins with N-terminal GST epitopes expressed in
baculovirus and afﬁnity puriﬁed under native conditions maintaining
their cellular enzymatic activities/native conformations. Technical
replicates of 8 plasma measured at 1:50, 1:150, 1:500 provided corre-
lation coefﬁents, R20.94-0.97 conﬁrming technical feasibility. In
order to identify targets of allo-Ab, pretransplant ﬂuorescent signal
intensities were subtracted from their one-year plasma results for all
5000 antigens. While Ab responses were unchanged for 4600 (92%)
antigens, new allo-Ab responses targeted 60-75 antigens with ﬂuores-
cent differences ranging 0.5 to 3 logs. In comparison with their
respective donor results, 30-40% appear to result from adoptive do-
nor transfer while the remaining develop de novo . Over 90% of
allo-Ab targets have known non-synonymous SNP which when dis-
parate in donor and recipient may elicit alloimmunity and this geno-
typing is ongoing. No single protein was recognized by “new” Ab
responses in all patients, however polymorphic proteins Growth Ar-
rest Speciﬁc-7 (GAS7), laminin A/C, and ribosomal protein S19
(RPS19) were recognized by two of the four patients after HCT.
Results from plasma samples collected 3, 6, 9 and 12 months after
HCT demonstrate the progression of alloimmune immune responses.
Though these novel mHA require validation by large clinically char-
acterized patient samples, protein microarrays are innovative, power-
ful tools for high-throughput global assessment of B -cell alloimmu-
nity after HCT providing sufﬁcient reproducibility for candidate
mHA discovery.
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EFFECTIVE GRAFT-VERSUS-LEUKEMIA RESPONSES ARE ASSOCIATED
WITH THE PRESENCE OF NUCLEIC ACID-IMMUNOGLOBULIN COM-
PLEXES THAT STIMULATE TOLL-LIKE RECEPTORS (TLR) 8 AND 9
Lin, Y.1, Means, T.4, Alyea, E.P.1,2,3, Canning, C.M.1,
Soiffer, R.J.1,2,3, Ritz, J.1,2,3, Wu, C.J.1,2,3 1Dana-Farber Cancer
Institute, Boston, MA; 2Department of Medicine, Brigham and Wom-
en’s Hospital, Boston, MA; 3Harvard Medical School, Boston, MA;
4Division of Rheumatology, Allergy and Immunology, Massaschusetts
General Hospital, Charlestown, MA.
In patients with chronic myeloid leukemia (CML) who demon-
strated effective graft-versus-leukemia (GvL) responses after DLI
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without clinically signiﬁcant GvHD, we previously identiﬁed a
panel of CML-associated antigens that are targets of antibodies
present in post-DLI sera. To gain insight into the possible mech-
anisms of immunogenicity of our GvL-associated target antigens,
we surveyed previously known cellular functions of our entire
panel of identiﬁed antigens, and observed that 70% are nucleic
acid binding proteins, thus predicting that sera from DLI respond-
ers may contain nucleic-acid containing activities that stimulate
immunity. Indeed, 5 of 6 post-DLI sera, but not pre-DLI sera,
induced a 3 to 50-fold increase in the expression of MIP-1alpha,
TNF-alpha, IP-10 and IFN-alpha transcripts in normal peripheral
blood mononuclear cells (PBMC). Cytokines were also not in-
duced by sera from 3 of 3 DLI non-responders or 3 of 3 CML
patients who achieved molecular remission after imatinib treat-
ment. This endogenous immunostimulatory factor required both
nucleic acid and protein for its adjuvant activity as pretreatment of
post-DLI sera with DNase, RNase, papain or pepsin resulted in
marked decrease in cytokine induction. To test for the role of
distinct TLRs in this response, HEK transfectants expressing
TLR3, 4, 8 or 9 were exposed to sera collected 6-12 months after
DLI. IL-8 expression increased only in the TLR8 and TLR9-
expressing cell lines that are known to be responsive to RNA and
DNA respectively. IL-8 expression was further induced by post-
DLI sera in TLR9-expressing cell lines co-transfected with CD32,
suggesting that internalization by FcR may enhance delivery of
nucleic acids to endosomal TLR8/9. None of the transfectants
could be activated by pre-DLI sera, nor by post-DLI sera from
non-responders. Finally, sera from responders collected as early as
2 weeks after DLI consistently activated TLR8 and 9 suggesting
that endogenous TLR8/9 activation may contribute to the early
immunologic events involved in effective DLI responses. Taken
together, these studies demonstrate for the ﬁrst time that effective
tumor immunity is correlated with the presence of endogenous
adjuvant-like nucleic-acid-immunoglobulin complexes in patient
sera. Ongoing studies are focused on studying the immunologic
effects of this endogenous adjuvant and determining which of our
previously identiﬁed CML antigens are bound to nucleic acids that
activate TLR8 and TLR9.
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CYTOTOXIC T LYMPHOCYTE RESPONSES TO PR1 PEPTIDE IN CML
PATIENTS INVERSELY CORRELATE WITH PROTEINASE 3 AND ELAS-
TASE EXPRESSION BUT DONOR PR1-RESPONSES DETERMINE MOLEC-
ULAR REMISSION AND DISEASE ERADICATION AFTER STEM CELL
TRANSPLANTATION
Yong, A.S.M.1, Rezvani, K.1, Savani, B.N.1, Eniafe, R.1, Mielke, S.1,
Goldman, J.M.1, Barrett, J.1 1NHLBI/NIH, Hematology Branch, 10
Center Drive, Bethesda, MD.
The primary granule proteins (PGP) neutrophil elastase (ELA2)
and proteinase 3 (PR3) both contain the nonapeptide PR1 which
can induce cytotoxic T lymphocyte (CTL) responses in chronic
myeloid leukemia (CML). The relative contribution of PR3 and
ELA2 to PR1 expression is not known. We previously found that
higher levels of PR3 and ELA2 gene expression in CD34 pro-
genitor cells were associated with longer survival in CML patients.
Eradication of leukemia requires elimination of leukemic stem
cells, which reside within the CD34 progenitor cell pool. We
therefore studied PGP expression and T cell response to PR1 in 31
CML patients and their HLA-identical family donors prior to
T-cell depleted allogeneic stem cell transplantation (SCT) with
T-cell add-back on day 45-100 post-SCT. CD8 T cells and
CD34 progenitor cells were puriﬁed from mononuclear cells
(MNC) of cryopreserved leukapheresis products from HLA-
A*0201 CML patients and their donors. ELA2 and PR3 gene
expression in MNC and CD34 cells was measured using real-
time quantitative polymerase chain reaction (RQ-PCR). To assess
PR1-CTL responses, T2 cells were loaded with PR1 peptide
(VLQELNVTV) and subsequently co-cultured with CD8 T
cells. PR1-CTL response was measured as interferon- mRNA
expression (relative to CD8) obtained by RQ-PCR. PR1-speciﬁc
CTL responses were detected in 7/28 CML patients and 7/27
HLA-identical donors. In CML patients, pre-SCT expression of
both PR3 and ELA2 in MNC was strongly correlated with the
expression in CD34 cells (p0.009 and p0.0006 respectively).
There was an inverse relationship between PR1-CTL response in
CML patients pre-SCT and PR3 or ELA2 expression (p0.02 and
p0.01 respectively). This data suggest that both PR3 and ELA2
expression in CD34 cells and their progeny are a potential source
of PR1. However, high expression of these proteins may result in
selective deletion of PR1 T cell clones. The presence of PR1-
responses in HLA-identical donors was associated with a signiﬁ-
cantly improved molecular remission rate from 3 months post-
SCT onwards, and moreover, was predictive of molecular
remission at 1-year post-SCT (p0.003). These ﬁndings support
peri-transplant vaccination strategies with PR1 peptide to eradicate
minimal residual disease. Conversely, in untransplanted patients,
the lower PR1 response in the presence of high PGP expression
suggests that vaccines given to patients with minimal residual
disease could result in tolerance to the leukemia.
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CD18 SEPARATES GVHD AND GVL EFFECT
Liang, Y.1, Anasetti, C.1, Yu, X.-Z.1 1H. Lee Mofﬁtt Cancer Center &
Research Institute, Tampa, FL.
Graft-versus-host disease (GVHD) remains a major cause of
morbidity and mortality in allogeneic hematopoietic stem cell
transplantation. Migration of donor-derived T cells into GVHD
target organs plays an essential role in the development of GVHD.
Beta2 integrins, a group of heterodimeric molecules including
CD11a/CD18 (LFA-1), CD11b/CD18 (Mac-1), CD11c/CD18
and CD11d/CD18, are of critical importance for leukocyte extrav-
asation through vascular endothelia and for T cell activation. We
asked whether CD18-deﬁcient T cells would induce less GVHD
while sparing graft-versus-leukemia (GVL) effect. In murine allo-
geneic bone marrow transplantation (BMT) models, we found that
recipients of CD18-/- donor T cells had signiﬁcantly less GVHD
morbidity and mortality compared with recipients of WT donor T
cells. A cell-dose titration experiment indicated that the ability of
CD18-/- T cells had more than 4-fold reduction compared to that
of WT T cells in the induction of GVHD. Analysis of alloreactive
showed that CD18-/- and WT T cells had comparable activation,
expansion and cytokine production in vivo. Reduced GVHD was
associated with a signiﬁcant decrease in donor-T cell inﬁltration of
recipient intestine and with an overall decrease in pathologic scores
in intestine and liver. Finally, we found that in vivo GVL effect of
CD18-/- donor T cells was largely preserved, because mortality of
the recipients transplanted with CD18-/- T cells plus tumor cells
was greatly delayed or prevented. Our data suggest that strategies
to target beta2 intergrin have clinical potential to alleviate or
prevent GVHD while sparing GVL activity.
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INHIBITION OF HMG-COA REDUCTASE ACTIVITY WITH STATINS PRO-
VIDES ACUTE-GRAFT-VERSUS-HOST DISEASE PROTECTION BY TH-2
CYTOKINE INDUCTION WHILE SPARING GRAFT-VERSUS-LEUKEMIA
ACTIVITY
Zeiser, R.1, Youssef, S.2, Baker, J.1, Steinman, L.2, Negrin, R.1 1Stan-
ford University Department of Medicine, Stanford, CA; 2Stanford Uni-
versity Department of Neurology, Stanford, CA.
The beneﬁcial impact of 3-hydroxy-3-methyl-CoA reductase in-
hibitors (statins) on autoimmunity and allograft rejection is well
documented. To investigate whether statins are capable of protect-
ing from acute graft vs host disease (aGVHD) we utilized an
established murine model (FVB/N into Balb/c). Type II statins
were potent inducers of a T-helper cell (Th)-2 cytokine proﬁle in
the adoptively transferred T cells upon exposure in vitro or in vivo.
Expansion of alloreactive luciferase transgenic T cells as measured
by total body light emission was signiﬁcantly reduced by donor
pre-treatment (10mg/kg) or in vitro T cell treatment (10nM) with
atorvastatin (AT vs PBS; p0.0008). The beneﬁcial effect of statin
treatment translated into signiﬁcantly reduced aGvHD lethality in
statin as compared to PBS treated animals. Th-2 biased donor T
cells could be tracked until day 25 after BMT. Host treatment
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